The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
Top Cited Papers
- 20 December 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 26 (1), 23-31
- https://doi.org/10.3109/09546634.2013.865009
Abstract
Background: To evaluate new psoriasis treatments, clinicians, regulators and pharmaceutical developers require well-accepted, clinically meaningful measures of disease severity. The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice. Objective: Characterize a 5-point Investigator’s Global Assessment (IGA) tool and evaluate whether it meets the needs for a valid, clinically meaningful measure. Methods: A 5-point IGA tool was developed with input from regulatory authorities and clinical trial investigators involved with psoriasis drug development and evaluation. Associations between IGA 0/1 responder rates and PASI scores were evaluated using data from two phase 2 studies with the anti-interleukin (IL)-17A monoclonal antibody secukinumab (AIN457) that utilized a similar 6-point IGA. Results: The 5-point IGA has a more stringent definition for a score of 1 (“almost clear”) compared with 6-point IGA/Physician’s Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis. Whereas IGA/PGA 0/1 responder rates for earlier scales are strongly associated with PASI 75, the IGA 0/1 rate for the secukinumab 6-point scale was more robust, demonstrating a strong association with PASI 90, and the results for the 5-point IGA are expected to show the same association. Discussion: The 5-point IGA is a valid measure of disease severity and meets the need for a clinically meaningful measure of success for psoriasis treatment studies.Keywords
This publication has 39 references indexed in Scilit:
- Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A?systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasisJournal of the American Academy of Dermatology, 2011
- How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic ReviewJournal of Investigative Dermatology, 2010
- What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literatureJournal of the European Academy of Dermatology and Venereology, 2010
- Psoriasis assessment tools in clinical trialsAnnals Of The Rheumatic Diseases, 2005
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004
- Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN SurveyJournal of Investigative Dermatology, 2003
- A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasisJournal of the American Academy of Dermatology, 1991
- Relationship of serum naproxen concentration to efficacy in rheumatoid arthritisClinical Pharmacology & Therapeutics, 1982
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978
- Cyclandelate in the Treatment of Senile Mental Changes: A Double-Blind EvaluationJournal of the American Geriatrics Society, 1977